High-Output vs Precision-Dosed: Comparing P58 and InhaleH2

The P58 (Hydrogen Machines) is a PEM electrolysis inhaler. A proton-exchange-membrane stack splits purified water and delivers a near-pure hydrogen stream (99.99% purity) at 1,000 ml/min total gas on Standard and 1,500 ml/min on Pro, taken via a nasal cannula. What comes out of the machine is almost entirely H₂ — the ml/min figure is close to the pure-hydrogen figure.

InhaleH2 uses a different design. A constant 11.6–12 L/min blended gas + air stream is delivered through an airtight mask, and the inhaled hydrogen fraction is adjustable between 0.1% and 4.0%. That is a deliberate safety and dosing design — a controlled low-concentration hydrogen dose in a large air stream, rather than raw high-purity output. Source: InhaleH2 official user manual, IH2-UM.001 (rev. 12.25), Product Specifications. Product page: https://inhaleh2.com/products/inhale-h2.

Neither approach is objectively superior on engineering merit. They are optimising for different things — one for high pure-hydrogen throughput, the other for precise, repeatable dosing over a longer masked sitting.

The P58 is built for maximum hydrogen exposure per session with a simple interface: fill the reservoir, connect the cannula, pick low or high, start. Best for households running a daily protocol who want a high-output near-pure stream and don't need dose-titration hardware.

InhaleH2 is built for repeatable controlled dosing with app-based session control, an airtight mask, and a breathing bag — a fixed low-concentration dose delivered the same way every time. Best for users who specifically want dose-titration, mask-based delivery, and the app-driven session logging that comes with it.

Neither is a verdict. They are legitimate different answers to the same broad question — how do you get hydrogen into someone reliably.

InhaleH2 retails direct at US$6,499 (≈A$9,400 at typical AUD rates). The P58 is US$2,050 (A$2,957) for the Standard flow tier and US$2,590 (A$3,736) for the Pro flow tier — roughly a third of InhaleH2's price.

For most people exploring hydrogen inhalation, and for anyone on a genuine budget, a US$6,499 device is out of reach regardless of engineering merit. That is not a technical superiority argument — it is a straight access argument. For that segment of buyers, a high-output near-pure-gas machine at roughly a third of the price is the only realistic option, and for them it is the practical better choice.

If US$6,499 is within reach and controlled low-concentration dosing, mask-based delivery, and a 3-year warranty are specifically what you want, InhaleH2 is a legitimate choice for those preferences. This is a real product trade-off, not a marketing framing.